Physician profile
Ryan Smith Weldon
NPI 1568724870
$457,692.51
in general payments reported to CMS, 2019-2025
34 companies · $83K in 2025
The $83K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $25K · 2021: $58K · 2022: $98K · 2023: $92K · 2024: $82K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $177K · Travel and Lodging: $24K · Consulting Fee: $22K · Food and Beverage: $19K · Honoraria: $14K · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $176,620.00 |
| Travel and Lodging | $23,729.80 |
| Consulting Fee | $22,075.00 |
| Food and Beverage | $19,131.39 |
| Honoraria | $14,437.50 |
| Education | $103.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $205,455.91 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $135,537.37 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44,795.19 | 2019-2025 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $25,383.28 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $16,203.49 | 2019-2025 | |
| Amgen INC. | $14,470.88 | 2019-2025 | Krystexxa, Otezla, Enbrel |
| Abbvie INC. | $5,635.80 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,573.10 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,545.33 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $1,445.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,112.45 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $779.88 | 2020-2025 | Acthar |
| Lilly USA, LLC | $637.21 | 2019-2025 | Taltz |
| Ani Pharmaceuticals, INC. | $448.96 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $376.57 | 2022-2025 | Lupkynis |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $342.23 | 2019-2024 | Tymlos |
| Genentech USA, INC. | $335.15 | 2019-2025 | Gazyva, Actemra |
| Medexus Pharma, INC. | $308.11 | 2019-2020 | |
| Organon LLC | $239.84 | 2024-2025 | Hadlima, Nexplanon |
| Genzyme Corporation | $217.82 | 2023-2025 | |
| Pacira Therapeutics, INC. | $168.28 | 2019-2021 | |
| Celgene Corporation | $146.80 | 2019 | |
| Sandoz INC. | $90.77 | 2023-2025 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $86.64 | 2019-2025 | Strensiq |
| Fresenius Kabi USA, LLC | $70.32 | 2023-2024 | Idacio |
| Sobi, INC | $50.67 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $44.73 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $42.55 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $38.64 | 2023-2024 | Zilretta |
| Regeneron Healthcare Solutions, INC. | $36.75 | 2019 | |
| Genentech, INC. | $24.60 | 2021 | |
| Medtronic, INC. | $17.89 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.56 | 2024 | Trulance |
| Celltrion USA INC. | $13.72 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Weldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.